WO2008035354A1 - Pastilles d'extraits d'herbes et son procédé de préparation - Google Patents

Pastilles d'extraits d'herbes et son procédé de préparation Download PDF

Info

Publication number
WO2008035354A1
WO2008035354A1 PCT/IN2006/000479 IN2006000479W WO2008035354A1 WO 2008035354 A1 WO2008035354 A1 WO 2008035354A1 IN 2006000479 W IN2006000479 W IN 2006000479W WO 2008035354 A1 WO2008035354 A1 WO 2008035354A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
percentage
range
final composition
pellets
Prior art date
Application number
PCT/IN2006/000479
Other languages
English (en)
Inventor
Anwar Siraj Daud
Jamaluddin Shamsuddin
Faiz Zakir Vali
Shakera Hussain
Mohammed Saleh Vali
Original Assignee
Unijules Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unijules Life Sciences Ltd. filed Critical Unijules Life Sciences Ltd.
Publication of WO2008035354A1 publication Critical patent/WO2008035354A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • This invention relates to a process and a product of coating herbal extracts on the surface of pellets or aggregates of inert particulate matter and optionally filling such pellets in capsules.
  • Herbal medicines are largely traditional. Solid dosage forms of products from medicinal plants and their extracts available in the market are restricted to the traditional dosage forms of powders, tablets and powders filled in capsules.
  • Process of preparation of a powder, a tablet or a capsule comprises use of crude herbal materials and extracts prepared from crude herbs.
  • the crude herbs are washed, dried, crushed, pulverized, and sifted through a suitable sieve and finally this powder is used as such, or converted into a tablet or filled up in capsule shells, usually made of hard gelatin or any other suitable material.
  • the prior art dosage forms thus, effectively delivered the plant material or its extract in a powder form, and its bioavailability and efficacy was limited by the efficacy with which the active principles of powder got released and absorbed in the digestive tract of the patient.
  • This invention embodies a process of delivering the herbal extracts, including a herbal drug, in a form of a coat over pellets, optionally applying a finishing coat and an optional color over the coated pellets, and filling the said coated pellets of one or more of an extract in the same capsule optionally with color coated non-pareil seeds.
  • the invention also describes a process of preparation of such pellets, a process of filling such pellets in capsule of hard gelatin or other material or pressing these pellets into tablets.
  • the invention is also embodied in the benefits it imparts to a herbal extract in general and a crude herbal extract in particular, of increase in the surface area of the extract several-fold resulting from applying and coating on inert beads of a suitable size made of an inert material, to facilitate improvement in bioavailability of the active ingredients.
  • This invention is also embodied in the products in the form of herbal pellets, herbal pellet filled capsules, the said capsules being transparent or otherwise.
  • This invention also embodies a method of preparing a dosage form in which physical contact between individual particles in a crude herbal extract with each other or between particles of two or more crude herbal extracts with each other is substantially limited or practically prevented.
  • the process essentially involves applying extract layer on a core of pellets of a suitable size consisting of an inert material available in the form of beads.
  • an inert material available in the form of beads.
  • Such inert beads are conventionally used in pharmaceutical science, and are readily available in market in all industrial countries.
  • the advantages of a process of coating of an extract on pellets is that the coating usually gives a uniform and continuous product coating. Aqueous or organic coatings can be applied. Coating and drying take place in one machine. In terms of containment, the coating process and the filling and emptying of the machine can be carried out in complete isolation and without product spreading into the environment.
  • the most preferred bead is one prepared from starch and sucrose, for use in confectionary as well as in pharmaceutical manufacturing.
  • beads of any pharmaceutically acceptable excipient may be used, including, for example, microcrystalline cellulose, vegetable gums, waxes, and the like.
  • the primary characteristic of the inert bead is to be inert, with regard both to extract and the other excipients in the pellet and with regard to the patient who will ultimately ingest the pellets.
  • the size of the beads depends, of course, on the desired size of the pellets to be manufactured. In general, pellets can be as small as 0.1 mm, or as large as 2 mm. Preferred beads are from about 0.3 to about 0.8 mm, in order to provide finished pellets in the desired preferred size range of from about 0.5 to about 1.5 mm in diameter.
  • the beads may be specified as being of particle size ranges such as from 14 to 20 U.S. mesh, from 20 to 25 U.S. mesh or from 25 to 35 U.S. mesh to obtain acceptable size distributions of various sizes.
  • the amount of beads to be used obviously depends on the weight and thickness of the added layers; in general, the beads comprise from about 15 to about 90 percent of the product. More preferably, the charge of beads should represent from about 20 to 65 percent of the product.
  • the extract is coated on the beads to yield a final drug concentration of about 1 to about
  • the amount of extract depends on the desired dose of the drug and the quantity of pellets, which it is desired to administer.
  • the usual amount of pellets is that amount which is conveniently held in gelatin capsules.
  • this process has been conducted in conventional coating pans similar to those employed in sugar coating processes. This process can be used to prepare pellets, but this equipment has less efficient air flow and drying capabilities which limits application rates and can result in longer processing times in order to minimize agglomerations. Alternately the present product could be made in fluidized bed equipment
  • the rotating plate equipment typically consists of a cylinder, the bottom of which is a rotatable plate. Motion of the mass of particles to be coated is provided by friction of the mass between the stationary wall of the cylinder and the rotating bottom of it. Means can be provided to apply warm air to dry the mass, and liquids can be sprayed on the mass and balanced against the drying rate as in the fluidized bed case.
  • Extract may be built up on the cores by spraying a slurry comprising extract suspended in a solution of the excipients, dissolved or suspended in sufficient water and lsopropyl alcohol (IPA) to make the slurry sprayable.
  • IPA lsopropyl alcohol
  • Such slurry may be milled through a machine adapted for grinding suspension in order to reduce the particle size of extract. Grinding in suspension form is desirable because it avoids dust generation and containment problems, which arise in grinding dry powder drugs.
  • a preferred method for applying this suspension is in the classic pharmaceutical fluidized bed coating device, which consists simply of a vertical cylinder with an air-permeable bottom and an upward spraying nozzle close above the bottom, or a downward-spraying nozzle mounted above the product mass.
  • the cylinder is charged with particles to be coated, sufficient volume of air is drawn through the bottom of the cylinder to suspend the mass of particles, and the liquid to be applied is sprayed onto the mass.
  • the temperature of the fluidizing air is balanced against the spray rate to maintain the mass of pellets at the desired level of moisture and stickiness while the coating is built up.
  • a finishing layer over the extract layer is not necessary in every case, but frequently improves the elegance of the product and its handling, storage and machinability and may provide further benefits as well.
  • the simplest finishing layer is simply a small amount, about less than 1 % of an anti- static ingredient such as talc or silicon dioxide, simply dusted on the surface of the pellets.
  • Another simple finishing layer is a small amount, about 1 %, of a wax such as beeswax melted onto the circulating mass of pellets to further smooth the pellets, reduce static charge, prevent any tendency for pellets to stick together, and increase the hydrophobicity of the surface.
  • More complex finishing layers may constitute a final sprayed-on layer of ingredients.
  • a thin layer of polymeric material such as hydroxypropyl methylcellulose, polyvinylpyrrolidone and the like, in an amount such as from about 2% up to about 10%, may be applied.
  • the polymeric material may also carry a suspension of an opacifier, a bulking agent such as talc, or a coloring material, particularly an opaque finely divided color agent such as red or yellow iron oxide.
  • a layer quickly dissolves away in the stomach, but provides an added measure of pharmaceutical elegance and protection from mechanical damage to the product.
  • Finishing layers to be applied to the present product are of essentially the same types commonly used in pharmaceutical science to make the surface smooth and shining, and color the products, and may be formulated and applied in the manners commonly known to a person skilled in the art of manufacture of pharmaceutical dosage forms.
  • the pellets coated with herbal extracts by process of this invention are dust free, round in shape, free flowing, with good dispersibility, decreased hygroscopicity, better uniformity in grain size distribution, with even distribution of drugs, and heavy metal content is also within recommended limits of W.H.O. and US F.D.A. i.e. for Lead, less than 10 ppm, for Cadmium less than 0.3 ppm, for Arsenic less than 10 ppm, and for Mercury 1 ppm.
  • This invention in general, is applicable to all herbal extracts that can be palletized in the way described in this invention.
  • This invention embodies capsules as an oral dosage form containing pellets coated with a herbal extract.
  • the pellets may be coated with only one extract or, when the extracts have no incompatibility with each other either for chemical reasons or when the extracts pertains to a pharmaceutical system where mixing extracts from two or more plants is not barred during preparation and storage of the product, the pellets may also be coated with more than one extract on the same batch.
  • the pellets may or may not be coated with a finishing layer.
  • the pellets containing a finishing layer may or may not contain a color or they may or may not be additionally colored.
  • the capsules may be filled with pellets of only one extract, or of more than one extract prepared in independent batches, with or without additional colored non-pareil seeds.
  • the increase in surface area leads to improvement in their bioefficacy and bioavailability without resorting to purification of an active ingredient, a method not complaint with Ayurveda, and without changing relative content of other ingredients in the crude extract prepared adhering to the recommended Ayurvedic practice.
  • Ayurvedic drug treatment is a traditional system of medicine in India based predominantly on use of extracts of medicinal plants prepared by ways scrupulously recommended by Ayurveda and validated for their medicinal effect by observations over several generations.
  • the medicinal plant extracts used in this system although crude, are highly specific for their efficacy only when prepared in the recommended way.
  • this invention provides a way to minimize a contact between particles of a crude extract with another particle of same or different extract packed and stored in same dosage form.
  • the coating is formulated with such ingredients which dissolve in the stomach, thus making available all the ingredients in original Ayurvedic intended form as it made fresh and delivered at the time of administration itself.
  • the drug coated pellets can be given an outer coating of different colour that distinguish one drug from the other and these can be blended and filled into transparent hard gelatin capsules. This improved elegance facilitated better acceptability and compliance to the product by the patient.
  • Vitex negundo Linn. Jain, P.K. and T.N.Pande : J. Res. Ind. Med. Yoga Homeo. 11 :2 (1976)
  • Tinospora cordifolia Tinospora cordifolia
  • Miers ex Hook. f. & Thorns. Pendse V.K. et al., Ind. J. Pharmacol. 9:221 (1977)
  • Curcuma longa Linn. (Deodhar SD, Sathi R, Srimal RC. Preliminary clinical study of anti-arthritic activity of Curcumin. Ind J Med Res 1902:71 :632-4.), Centella asiatca Linn. (Bhargava R.K. and Soni V.
  • Herbal extracts mentioned above are prepared with any of the method known to the pharmaceutical art as per methods indicated in the related literature, mainly based on soxhlet extraction. Solvent or a mixture of solvent may be used to get total extracts. Solvent may be water , hydroalcoholic, acetone .hexane or any solvent reported in the literature for preparing herbal extracts.
  • a herbal extract for the purpose of application of this invention can also be prepared by using any other plant part by using a solvent not mentioned herein or by a method not mentioned herein. Methods of preparation extract mentioned here are only illustrative in nature.
  • a herbal extract for the purpose of application of this invention may also be prepared by any of the other methods as long as it can be coated on the pellets by one or the other methods.
  • a method of peptization includes “one or more methods of pelletization”.
  • Mention of "an extract” includes one or more than one extract.
  • Mention of a generic word is construed to include all members of its own kind, singly or in combination which can perform the claimed function in the alternative.
  • a solvent includes mention of all solvents, individually as well a collectively which can be used in the alternative to serve the same function as described.
  • Non-pareil seeds mentioned in the examples are inert beads as mentioned above, which are easily available in market and are commonly known in production of Pharmaceutical dosage forms based on pelletization. EXAMPLE 1 PREPARATION OF ANTIEMETIC PELLETS Materials taken per 150 kg batch of antiemetic pellets Non-pareil seeds (N. P. seeds 18-20#) 62 kg
  • Demineralised water 25 litres lsopropyl alcohol 12.5 litres
  • HPMC-5cps 0.15 kg Zingiber officinale Roxb. extract and Piper longum Linn, extract were dispersed in separate batches of hot demineralised water to which was added isopropyl alcohol in which HPMC-5cps was dispersed. Each mixture was mixed thoroughly. Non-pareil seeds are put in Fluidized Bed equipment and above extract dispersions were sprayed on two separate batches through peristaltic pump at 50 rpm, over NP seeds, keeping bed temperature at 60 0 C. After extract layer was fully formed, finishing layer was applied over each batch of the pellets as described in the follows.
  • Talc and Titanium were added. This dispersion was sprayed in a fluidized bed equipment through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C.
  • HPMC HPMC was dispersed in IPA, PEG-6000 was added in it, water was gradually added to make solution, permitted colour was added, and talc and titanium dioxide was suspended in it. In one solution brilliant Blue was used as permitted color and in second solution, erythrosine was used as permitted color.
  • Herbal extracts finished and colored pellets as prepared above can also be compressed into tablets as follows. Composition per tablet
  • Herbal extracts pellets are mixed with Microcrystalline cellulose spray dried and
  • Lactose directly compressible Further this mixture is lubricated with magnesium stearate and talc. This mixture is compressed into tablet as per the procedure known to the art of pharmacy.
  • Non-pareil seeds N. P. seeds 18-20# 45 kg
  • Vitex sp., Tinospora sp. and Curcuma sp. were prepared by the same process as done with the product of Example-1 , without finishing layer. Finally, the prepared herbal pellets were filled into capsules in desired proportions and with N. P. seeds
  • Non-pareil seeds (N. P. seeds 18-20#) 100 kg
  • Demineralised water 50 litres lsopropyl alcohol 25 litres HPMC-5cps 2.5 kg
  • Demineralised water 15 litres lsopropyl alcohol 10 litres
  • Example-1in separate two batches with each herbal extract without colouring the pellets. Finally the prepared herbal pellets were filled into capsules with coloured
  • N. P. seed. Colouring of N. P. seed was done as follows. N. P. seed 16-20# 100 kg
  • HPMC HPMC was dispersed in IPA, add water slowly to make solution, dissolve colour & PEG and suspend titanium and talc. Put N. P. seed in Fluid Bed Coater and proceeded with the coating operation as in Example-1 by spraying the colour suspension and finally continuing air for further 15 minutes to dry the pellets.
  • Non-pareil seeds (N. P. seeds 18-20#) 65 kg
  • Benth. extract were dispersed in separate batches of hot demineralised water to which was added isopropyl alcohol in which HPMC-5cps was dispersed. Each mixture was mixed thoroughly. Non-pareil seeds are put in Fluidized Bed equipment and above extract dispersions were sprayed on two separate batches through peristaltic pump at 50 rpm, over NP seeds, keeping bed temperature at
  • HPMC ⁇ 5cps was dispersed in IPA; water was added slowly while stirring, and further Talc and Titanium were added. This dispersion was sprayed in fluidized bed equipment through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C.
  • HPMC HPMC was dispersed in IPA, PEG-6000 was added in it, water was gradually added to make solution, permitted colour was added, and talc and titanium dioxide was suspended in it. Sunset yellow was used as permitted color.
  • These dispersions with one color were sprayed in a fluidized bed equipment, through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C, over talc-titanium layer of the herbal pellets of the extract of plant to which that colour was designated. When the addition was complete, airflow was continued for 15 minutes to dry the batch. Prior to filling into capsules, herbal pellets were mixed with N. P. seeds with green colour utilizing Brilliant Blue & Tartrazine colour to match the net desired content.
  • Non-pareil seeds N. P. seeds 18-20# 150 kg Withania somnifera Dunal. extract 4.0 kg
  • Demineralised water 40 litres lsopropyl alcohol 20 litres Withania somnifera Dunal. extract, Bacopa monnieri Linn, extract, and
  • Nardostachys jatamansi DC. extract were dispersed in separate batches of hot demineralised water to which was added isopropyl alcohol. Each mixture was mixed thoroughly. Non-pareil seeds are put in Fluidized Bed equipment and above extract dispersions were sprayed on two separate batches through peristaltic pump at 50 rpm , over NP seeds, keeping bed temperature at 60 0 C.
  • HPMC-5cps was dispersed in IPA; water was added slowly while stirring, and further Talc and Titanium were added. This dispersion was sprayed in fluidized bed equipment through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C.
  • HPMC HPMC was dispersed in IPA, PEG-6000 was added in it, water was gradually added to make solution, permitted colour was added, and talc and titanium dioxide was suspended in it. Sunset yellow was used as permitted color.
  • Non-pareil seeds (N. P. seeds 18-20#) 150 kg
  • Tribulus terrestris Linn extract 11.5 kg Demineralised water 80 litres lsopropyl alcohol 40 litres
  • Boerhavia diffusa Linn, extract, and Tribulus terrestris Linn, extract were dispersed in separate batches of hot demineralised water to which was added isopropyl alcohol in which HPMC was added. Each mixture was mixed thoroughly. Non-pareil seeds are put in Fluidized Bed equipment and above extract dispersions were sprayed on two separate batches through peristaltic pump at 50 rpm, over NP seeds, keeping bed temperature at 60 0 C. After extract layer was fully formed, finishing layer was applied over each batch of the pellets as described in the follows.
  • HPMC-5cps was dispersed in IPA; water was added slowly while stirring, and further Talc and Titanium were added. This dispersion was sprayed in fluidized bed equipment through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C.
  • These dispersions with one color were sprayed in a fluidized bed equipment, through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C, over talc-titanium layer of the herbal pellets of the extract of plant to which that colour was designated. When the addition was complete, airflow was continued for 15 minutes to dry the batch. Prior to filling into capsules, herbal pellets were mixed with N. P. seeds to match the net desired content.
  • Non-pareil seeds (N. P. seeds 18-20#) 150 kg
  • HPMC-5cps was dispersed in IPA; water was added slowly while stirring, and further Talc and Titanium were added. This dispersion was sprayed in fluidized bed equipment through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C.
  • HPMC HPMC was dispersed in IPA, PEG-6000 was added in it, water was gradually added to make solution, permitted colour was added, and talc and titanium dioxide was suspended in it. Tartrazine was used as permitted color. These dispersions with one color were sprayed in a fluidized bed equipment, through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C, over talc-titanium layer of the herbal pellets of the extract of plant to which that colour was designated. When the addition was complete, airflow was continued for 15 minutes to dry the batch. Prior to filling into capsules, herbal pellets were mixed with brown NP. seeds utilizing caramel colour to match the net desired content.
  • Non-pareil seeds N. P. seeds 18-20# 150 kg
  • HPMC HPMC was dispersed in IPA, PEG-6000 was added in it, water was gradually added to make solution, permitted colour was added, and talc and titanium dioxide was suspended in it. Tartrazine and Brilliant Blue were used as permitted color. These dispersions of color were sprayed in a fluidized bed equipment, through peristaltic pump at 50 rpm over the extract layer keeping bed temperature at 60 0 C, over talc-titanium layer of the herbal pellets of the extract of plant to which that colour was designated. When the addition was complete, airflow was continued for 15 minutes to dry the batch. Prior to filling into capsules, herbal pellets were mixed with pink colour NP. seeds utilizing erythrosine colour to match the net desired content.
  • Non-pareil seeds N. P. seeds 18-20# 150 kg
  • Titanium Dioxide 1.0 kg IPA 10 litres
  • HPMC HPMC was dispersed in IPA, PEG-6000 was added in it, water was gradually added to make solution, permitted colour was added, and talc and titanium dioxide was suspended in it. Brilliant Blue was used as permitted color.
  • Non-pareil seeds (N. P. seeds 18-20#) 100 kg
  • HPMC-5cps 1.25 kg Asparagus racemosus WiIId. extract, Allium sativum Linn, extract, Euphorbia hirta Linn, extract Pueraria tuberosa DC. extract Leptadenia raticulata Wight and Arn. extract, Trigonella foenum-graecum Linn, extract and Withania somnifera Dunal. extract were dispersed in separate batches of hot demineralised water to which was added isopropyl alcohol in which HPMC-5cps was dispersed. Each mixture was mixed thoroughly. Non-pareil seeds are put in Fluidized Bed equipment and above extract dispersions were sprayed on two separate batches through peristaltic pump at 50 rpm, over NP seeds, keeping bed temperature at 60 0 C. After extract layer was fully formed, finishing layer was applied over each batch of the pellets as described in the follows. FINISHING LAYER APPLICATION Ingredients:
  • NP seeds in coating pan Disperse the extract in a mixture of Talc, HPMC & IPA separately and for both the extracts and separately pour in 5 litres instalments. The extract mixture over NP seeds put in coating pan with 15 rpm.
  • Dispers HPMC in IPA dissolve PEG 6000 in it, add methylene chloride, to make solution.
  • Disperse HPMC in IPA add water to it and make solution, disperse talc in it. Take NP seed in rotating pan at 12 rpm, wet the NP seed with above dispersion of talc and HPMC by spray gun and dust the herbal dry extract over wetted NP seed. In this way dust complete individual dry herbal extract separately and dry at 60° C in oven for 12 hrs.
  • Non-pareil seeds (N. P. seeds 18-20#) 100 kg
  • Centella asiatica Linn extract 7.2 kg PEG-6000 0.1 kg Demineralised water 50 litres lsopropyl alcohol 25 litres
  • Demineralised water 15 litres lsopropyl alcohol 10 litres
  • the extracts of the both herbs are combined and disperse in hot demineralized water, to which added isopropyl alcohol, PEG6000, HPMC talc and titanium dioxide.
  • Non-pareil seeds are put in Fluidized Bed equipment and above extract dispersions were sprayed through peristaltic pump at 50 rpm, over NP seeds, keeping bed temperature at 60 0 C. After extract layer was fully formed, colouring of N. P. seed was done as follows.
  • Titanium Dioxide 0.5 kg IPA (isopropyl alcohol) 5.0 liters
  • HPMC HPMC was dispersed in IPA, add water slowly to make solution, dissolve colour

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une nouvelle posologie orale pour l'administration d'un ou de plusieurs extraits d'herbes et son procédé de préparation, un extrait d'herbes étant enrobé sur des pastilles et lesdites pastilles étant soit remplies dans une capsule soit comprimées en une pilule. Ladite capsule peut contenir des pastilles enrobées avec un ou des extraits d'herbes et ladite pilule est comprimée à partir de pastilles enrobées avec au moins deux extraits d'herbes. L'invention concerne également un procédé de préparation de ladite posologie.
PCT/IN2006/000479 2006-09-21 2006-11-29 Pastilles d'extraits d'herbes et son procédé de préparation WO2008035354A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1514/MUM/2006 2006-09-21
IN1514MU2006 2006-09-21

Publications (1)

Publication Number Publication Date
WO2008035354A1 true WO2008035354A1 (fr) 2008-03-27

Family

ID=39200225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000479 WO2008035354A1 (fr) 2006-09-21 2006-11-29 Pastilles d'extraits d'herbes et son procédé de préparation

Country Status (2)

Country Link
MY (1) MY158075A (fr)
WO (1) WO2008035354A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938430A1 (fr) * 2008-11-14 2010-05-21 Debregeas Et Associes Pharma Granules a base de plantes
WO2020144591A3 (fr) * 2019-01-09 2020-09-03 Antony Benny Préparation de withanoside x purifié à partir de matériaux végétaux de withania somnifera et son utilisation médicinale pour le traitement de troubles de la santé
EP3782609B1 (fr) * 2019-08-21 2023-11-01 Tae Hun Ku Formulation de pastilles contenant un extrait d'herbes simple ou complexe à haute concentration et son procédé de fabrication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047551A1 (fr) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040081691A1 (en) * 1999-03-12 2004-04-29 D B F Granules containing a plant substance and process for preparing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081691A1 (en) * 1999-03-12 2004-04-29 D B F Granules containing a plant substance and process for preparing them
WO2003047551A1 (fr) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938430A1 (fr) * 2008-11-14 2010-05-21 Debregeas Et Associes Pharma Granules a base de plantes
WO2010055252A3 (fr) * 2008-11-14 2010-08-12 Debregeas Et Associes Pharma Granulés à base de plantes
WO2020144591A3 (fr) * 2019-01-09 2020-09-03 Antony Benny Préparation de withanoside x purifié à partir de matériaux végétaux de withania somnifera et son utilisation médicinale pour le traitement de troubles de la santé
EP3782609B1 (fr) * 2019-08-21 2023-11-01 Tae Hun Ku Formulation de pastilles contenant un extrait d'herbes simple ou complexe à haute concentration et son procédé de fabrication

Also Published As

Publication number Publication date
MY158075A (en) 2016-08-30

Similar Documents

Publication Publication Date Title
Byeon et al. Recent formulation approaches to oral delivery of herbal medicines
TWI481410B (zh) 克羅非莫(crofelemer)用於治療與腹瀉型腸躁症(d-IBS)相關聯之腹痛及腹部不適的醫藥用途
AU2020280997B2 (en) A process to enhance the bioactivity of Ashwagandha extracts
CN105934161A (zh) 含有油性的，辛辣的，有气味的物质的组合物和其制备方法
US9987323B2 (en) Process to enhance the bioactivity of Ashwagandha extracts
CN103610659A (zh) 一种大蒜素药物组合物及其制备方法
WO2008035354A1 (fr) Pastilles d'extraits d'herbes et son procédé de préparation
WO2008059522A2 (fr) Formes posologiques d'administration contrôlée de médicament gastro-intestinale à base d'herbe comprenant des pastilles et leur procédé de préparation
CN101721673A (zh) 一种疏肝理气、化痰利咽制剂及其制备方法
CN110623998A (zh) 一种用于糖尿病周围神经病变的中药组合物及其应用
JP4601069B2 (ja) 高脂血症治療のための相乗効果的医薬組成物
WO2001054673A1 (fr) Procede de preparation et d'administration de materiau a base de plante medicinale
CN101496903B (zh) 一种减少药物对胃刺激的药物包衣液
WO2007071708A2 (fr) Fraction de gingembre pour inhiber des enzymes cyp humaines
Katrolia et al. Exploring the Therapeutic Potential of Herbal Plants in Managing Blood Sugar Levels: A Comprehensive Evaluation
US20230233642A1 (en) Process to enhance the bioactivity of ashwagandha extracts
Bakshi et al. Herbal Bioactive-Based Drug Delivery Systems: Challenges and Opportunities
Icame Development of the composition and technology of tablets with turmeric root powder and black pepper extract
CN109432082A (zh) 一种防治化学性肝损伤的药物组合物
WO2003055558A1 (fr) Composition de plusieurs herbes medicinales pour traiter d'asthme bronchique, et procede de preparation
TW202320833A (zh) 一種治療心肌缺血的藥物組合物及其製備方法
Huang et al. Film-Controlled Synchronized Release Multicomponent Preparations of Chinese Materia Medica for Oral Administration
GB2623163A (en) Oral composition for perimenopause
JP2003135023A (ja) 健康食品
CN112386667A (zh) 一种治疗冠心病的中药丸剂配方及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06847326

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847326

Country of ref document: EP

Kind code of ref document: A1